CN118119624A - 具有病毒增殖抑制作用的核苷衍生物及其前药 - Google Patents

具有病毒增殖抑制作用的核苷衍生物及其前药 Download PDF

Info

Publication number
CN118119624A
CN118119624A CN202280069993.0A CN202280069993A CN118119624A CN 118119624 A CN118119624 A CN 118119624A CN 202280069993 A CN202280069993 A CN 202280069993A CN 118119624 A CN118119624 A CN 118119624A
Authority
CN
China
Prior art keywords
group
hydrogen
substituted
substituent group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069993.0A
Other languages
English (en)
Chinese (zh)
Inventor
加藤一生
金田雅仁
宫川雅好
山本棱太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN118119624A publication Critical patent/CN118119624A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202280069993.0A 2021-08-20 2022-08-19 具有病毒增殖抑制作用的核苷衍生物及其前药 Pending CN118119624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021134801 2021-08-20
JP2021-134801 2021-08-20
PCT/JP2022/031308 WO2023022216A1 (ja) 2021-08-20 2022-08-19 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ

Publications (1)

Publication Number Publication Date
CN118119624A true CN118119624A (zh) 2024-05-31

Family

ID=85240607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069993.0A Pending CN118119624A (zh) 2021-08-20 2022-08-19 具有病毒增殖抑制作用的核苷衍生物及其前药

Country Status (12)

Country Link
US (1) US20250170155A1 (https=)
EP (1) EP4389750A4 (https=)
JP (1) JPWO2023022216A1 (https=)
KR (1) KR20240050362A (https=)
CN (1) CN118119624A (https=)
AU (1) AU2022331233A1 (https=)
CA (1) CA3229752A1 (https=)
CO (1) CO2024003018A2 (https=)
IL (1) IL310854A (https=)
MX (1) MX2024002116A (https=)
PE (1) PE20240654A1 (https=)
WO (1) WO2023022216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3277623D1 (en) 1981-07-31 1987-12-17 Sloan Kettering Inst Cancer Anti-leukemic beta-glycosyl c-nucleosides
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2007069924A1 (en) 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
MX2009007333A (es) * 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
US9290501B2 (en) 2010-11-29 2016-03-22 Albert Einstein College Of Medicine, Inc. Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
MD4496C1 (ro) * 2012-03-13 2018-02-28 Gilead Sciences, Inc. Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗ウイルス性アザ糖を含有するヌクレオシド
CA2911424C (en) 2013-05-14 2021-11-30 Biocryst Pharmaceuticals, Inc. Anti-influenza imino-ribose pyrrolopyrimidine derivatives
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN107108683A (zh) 2014-10-31 2017-08-29 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
CN110678473A (zh) 2017-04-25 2020-01-10 大原药品工业株式会社 核苷类抗癌药或抗病毒药的5’位二苄基单磷酸酯衍生物
WO2018230479A1 (ja) 2017-06-13 2018-12-20 大原薬品工業株式会社 ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2021040356A1 (en) 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN112062800B (zh) 2020-09-02 2022-11-18 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途
CN112010916B (zh) 2020-09-09 2022-12-27 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途

Also Published As

Publication number Publication date
KR20240050362A (ko) 2024-04-18
WO2023022216A1 (ja) 2023-02-23
MX2024002116A (es) 2024-03-06
EP4389750A4 (en) 2025-10-01
CA3229752A1 (en) 2023-02-23
EP4389750A1 (en) 2024-06-26
JPWO2023022216A1 (https=) 2023-02-23
AU2022331233A1 (en) 2024-02-29
IL310854A (en) 2024-04-01
US20250170155A1 (en) 2025-05-29
PE20240654A1 (es) 2024-04-04
CO2024003018A2 (es) 2024-03-18

Similar Documents

Publication Publication Date Title
CN118119624A (zh) 具有病毒增殖抑制作用的核苷衍生物及其前药
CN113226327B (zh) 可用于治疗流感病毒感染的化合物
JP6267397B1 (ja) 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
EP3917527B1 (en) Compounds and uses thereof
EP4549442A1 (en) Prmt5 inhibitors and use thereof
US11332465B2 (en) Diarylthiohydantoin compound as androgen receptor antagonist
CA2943220A1 (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
JP7624093B2 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
US20230110550A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
EP3475285B1 (en) Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof
CN116390925A (zh) Ampk活化剂
CN116528850B (zh) 具有抗病毒活性的酰胺衍生物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
JP7329052B2 (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
KR102539761B1 (ko) 2-티옥소티아졸리딘-4-온 유도체 화합물 및 이의 용도
EP3653626B1 (en) Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same
CN119241496A (zh) 外核苷酸焦磷酸酶/磷酸二酯酶1抑制剂及其制法和用途
HK40050168B (en) Compounds useful to treat influenza virus infections
HK40050168A (en) Compounds useful to treat influenza virus infections
TW202535350A (zh) 一種tdg抑制劑化合物及其用途
CN117999257A (zh) 具有病毒增殖抑制活性的双环杂环衍生物及含有其的药物组合物
FR3025200A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
HK40002867A (en) Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof
OA20831A (en) Methods for treating filoviridae virus infections.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination